Literature DB >> 2220936

Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women.

J E Nestler1, R Singh, D W Matt, J N Clore, W G Blackard.   

Abstract

Suppression of serum insulin levels with diazoxide is associated with a decrease in serum testosterone and an increase in serum sex hormone-binding globulin in obese women with the polycystic ovary syndrome. To determine whether physiologic insulin levels play a regulatory role in the androgen status of nonobese women with normal menses, the androgen status of five nonobese normal women was assessed on two occasions: during a control study and after 10 days of oral diazoxide (100 mg, three times daily) administration. Insulin release in response to 100 gm oral glucose administration decreased from 108.0 +/- 28.2 to 49.3 +/- 5.2 nmol.min/L (p = 0.05) after diazoxide administration. However, despite suppression of insulin release, diazoxide administration did not affect serum total testosterone (diazoxide, 0.73 +/- 0.10; control, 0.69 +/- 0.11 nmol/L; p = NS) or sex hormone-binding globulin (diazoxide, 79.7 +/- 16.6; control, 70.2 +/- 12.6 nmol/L; p = NS) concentrations. These observations suggest that physiologic insulin levels in nonobese healthy women do not regulate testosterone metabolism and that diazoxide does not exert a direct or independent effect on serum testosterone or sex hormone-binding globulin levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2220936     DOI: 10.1016/0002-9378(90)90698-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  PCOS in adolescence and type 2 diabetes.

Authors:  Anne-Marie Carreau; Jean-Patrice Baillargeon
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

2.  Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome.

Authors:  Edmond P Wickham; Kai I Cheang; John N Clore; Jean-Patrice Baillargeon; John E Nestler
Journal:  Metabolism       Date:  2010-03-31       Impact factor: 8.694

Review 3.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

4.  Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.

Authors:  Jean-Patrice Baillargeon; André Carpentier
Journal:  Fertil Steril       Date:  2007-06-07       Impact factor: 7.329

5.  Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome.

Authors:  A Vidal-Puig; M Muñoz-Torres; C Garcia-Calvente; E Jodar-Gimeno; P Lardelli; M E Ruiz-Requena; F Escobar-Jiménez
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

Review 6.  Insulin and hyperandrogenism in women with polycystic ovary syndrome.

Authors:  Catherine G Baptiste; Marie-Claude Battista; Andréanne Trottier; Jean-Patrice Baillargeon
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-28       Impact factor: 4.292

Review 7.  Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.

Authors:  R J Klement; M K Fink
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

Review 8.  Polycystic Ovary Syndrome: Implication for Drug Metabolism on Assisted Reproductive Techniques-A Literature Review.

Authors:  Enrique Reyes-Muñoz; Thozhukat Sathyapalan; Paola Rossetti; Mohsin Shah; Min Long; Massimo Buscema; Gaetano Valenti; Valentina Lucia La Rosa; Stefano Cianci; Salvatore Giovanni Vitale
Journal:  Adv Ther       Date:  2018-10-11       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.